Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Farmers Urged To Remain Vigilant To Prevent Bluetongue Taking Hold
Farmers are once again being urged to vaccinate their livestock against the threat of bluetongue. The warning from the Joint Action against Bluetongue campaign (JAB) comes as the country enters the height of summer meaning midge activity is reaching a peak period and the risk of a bluetongue incursion increases on a daily basis.
generic viagra online
New EPI Healthcare Study By June O'Neill Shows Uninsured 'Crisis' Wildly Overestimated
The Employment Policies Institute (EPI) released a new study which shows that the widely employed estimate of 47 million uninsured Americans is a misleading representation of the problem. The study, authored by Drs. June and David O"Neill of Baruch College and City University of New York, shows that more than 43 percent, or 18 million, of uninsured Americans ages 18-64 could likely afford health coverage and are actually "voluntarily uninsured." June O"Neill served as Director of the Congressional Budget Office (CBO) from 1995-1999.
News of the day
Revealing Leukemia-Initiating Cells
Two new studies reveal a way to increase the body"s appetite for gobbling up the cancer stem cells responsible for acute myeloid leukemia (AML), a form of cancer with a particularly poor survival rate. The key is targeting a protein on the surface of those cells that sends a "don"t eat me" signal to the macrophage immune cells that serve as a first line of defense, according to the reports in the July 24th issue of the journal Cell, a Cell Press publication.
Mental Health

ImmunoCellular Therapeutics Announces Filing Of Key Patent Application Relating To Cancer Stem Cell Technology

ImmunoCellular Therapeutics, Ltd. (OTC: IMUC.OB) (IMUC), a biotechnology company, announced the filing of a provisional U.S. patent application relating to its novel vaccine technology targeting cancer stem cells. The patent application relates to new peptide candidates that may significantly expand the potential target patient population for the company"s cancer stem cell vaccine product candidate, ICT-121. Many cancer therapies are limited by their ability to be used only in patients with certain human leukocyte antigen (HLA) types. Identification of the new peptides for use in IMUC"s vaccine should enable the use of IMUC"s product candidate in patients with many different HLA types. The Company currently has 25 issued or pending patents. "This patent application supports our broad and growing portfolio of intellectual property. ICT-121 is an immunotherapy that targets cancer stem cells - a very exciting approach given the product"s mission of destroying cancer cells at their root as well as its proven ability in preclinical studies to be highly targeted for destroying cancer cells," stated Manish Singh, Ph.D., president and chief executive officer of IMUC. "This product may have applicability to multiple types of cancer, but our first clinical target will be glioblastoma. We anticipate filing an Investigational New Drug (IND) application next quarter to begin a Phase I clinical trial of ICT-121." About ICT-121 ICT-121 is IMUC"s cancer stem cell (CSC) vaccine product candidate that consists of a peptide to stimulate a cytotoxic T-lymphocyte (CTL) response to CD133, which is generally overexpressed on the CSCs. It is designed as an "off-the-shelf" vaccine. IMUC will initially evaluate it in a Phase I clinical study for glioblastoma which the company expects to file an IND for in the third quarter of this year. While glioblastoma will be the initial target for ICT-121, CD133 is also overexpressed in colon cancer, breast cancer, liver cancer, prostate cancer, multiple myeloma and melanoma, providing many potential cancer targets for this CSC vaccine in the future. ImmunoCellular Therapeutics, Ltd.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009